Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Average Target Price from Analysts

Immuneering Co. (NASDAQ:IMRX) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $12.60.

A number of analysts have weighed in on the company. Chardan Capital decreased their price objective on Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research report on Friday, September 13th.

Immuneering Price Performance

Shares of Immuneering stock opened at $2.47 on Tuesday. The firm’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.63. Immuneering has a 12 month low of $1.00 and a 12 month high of $8.89. The stock has a market capitalization of $73.24 million, a price-to-earnings ratio of -1.32 and a beta of -0.45.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Analysts anticipate that Immuneering will post -1.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IMRX. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Immuneering during the 2nd quarter worth $44,000. XTX Topco Ltd grew its position in Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after buying an additional 9,274 shares during the period. Acadian Asset Management LLC purchased a new position in Immuneering in the second quarter valued at about $67,000. Renaissance Technologies LLC purchased a new position in Immuneering in the second quarter valued at about $447,000. Finally, Marshall Wace LLP acquired a new stake in shares of Immuneering during the 2nd quarter valued at approximately $492,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.